产品特点
Issued: March 2011
AN: 02036/2009 1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
MAXXENE SPOT ON SOLUTION DOG M 134 mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Fipronil………………………………………………………………10%
w/v
Butylhydroxyanisole E320……………………………………...
0.02% w/v
Butylhydroxytoluene E321………………………………….…..
0.01% w/v
Non-aqueous vehicle
qs…………………………………….……… to 100%
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Spot-on solution
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs weighing over 10kg and up to 20kg bodyweight
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
The treatment and prevention of infestations by fleas and ticks and as
part of a treatment strategy for Flea Allergy Dermatitis, where this
has been
been previously diagnosed by a veterinary surgeon. The product
controls
infestations with _Trichodectes canis_ biting lice on dogs.
4.3
CONTRA-INDICATIONS
Do not use on sick (systemic diseases, fever…) or convalescent
animals.
Do not use in rabbits, as adverse reactions and even death could
occur.
This product is specifically developed for dogs. Do not use in cats,
as this
could lead to overdosing.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Avoid contact with the animal’s eyes.
When treating infestations of lice, all in-contact dogs should be
treated
with an appropriate product at the same time.
The product does not prevent ticks from attaching to the animals, but
ticks
will be killed in the first 24-48 hours after attachment, prior to
full
engorgement and therefore minimising the risk of transmission of
diseases.
Once dead, ticks will often drop off the animal, but any remaining
ticks may
easily be removed by a gentle pull.
Page 1 of 8
Issued: March 2011
AN: 02036/2009
Bathing or shampooing the animal up to one hour prior to treatment
does not
affect the efficacy of the product.
When used as part of a strategy for the treatment of Flea Allergy
Dermat
阅读完整的文件
产品特点 